KVAC has entered into a letter of intent with Medera and its subsidiary Novoheart for a potential business combination involving pre-clinical human disease modeling and drug discovery technologies. Recent news highlights a partnership between Medera’s Novoheart and Curi Bio for human-based cardiac drug screening.

• KVAC executed a letter of intent with Medera and Novoheart to negotiate a replacement merger agreement by April 10, 2026, aiming to complete a business combination focused on pre-clinical human disease modeling and drug discovery [S1].
• The letter of intent sets Novoheart’s enterprise valuation at $100 million and outlines cash availability requirements at closing [S1].
• Recent news reports a partnership between Medera’s Novoheart and Curi Bio for human-based cardiac drug screening, indicating active development in the target’s technology area [N1].

KVAC’s experienced management team and sponsors bring a strong track record in private equity and de-SPAC transactions, which could facilitate the identification and acquisition of a high-potential target company. The focus on biotech, consumer goods, and agriculture sectors with ESG considerations aligns with growing market interest in sustainable and innovative businesses. The company’s substantial trust account assets provide financial resources to support a meaningful business combination. The recent letter of intent with Medera and Novoheart indicates progress toward consummating a business combination involving advanced pre-clinical human disease modeling and drug discovery technologies, which could position the combined entity in a niche with growth potential.

KVAC faces typical SPAC risks, including the challenge of identifying and completing a suitable business combination within the prescribed timeframe. The company’s current liquidity position outside the trust account is limited, with a low current ratio and working capital deficit, which may constrain operational flexibility. The business combination with Medera and Novoheart is subject to negotiation and approval risks, and the final structure and timing remain uncertain. Market and regulatory risks, particularly if the target operates in complex jurisdictions such as China, could impact the combined company’s performance. Additionally, the company’s success depends on the ability to integrate and grow the target business post-combination, which carries execution risk.

KVAC’s moat is primarily derived from its experienced management team and sponsors with decades of combined expertise in private equity, de-SPAC transactions, and cross-border mergers and acquisitions. Their extensive global networks and operational experience in biotech, consumer goods, and agriculture sectors provide access to a broad pipeline of potential acquisition targets. The company’s focus on ESG imperatives and rigorous due diligence processes aim to identify resilient, high-growth companies that can benefit from public market access and operational improvements. However, as a SPAC without an operating business, its moat depends on successful execution of its initial business combination and subsequent value creation.

• Execution Risk of Business Combination: KVAC has not yet completed its initial business combination. The ability to identify, negotiate, and consummate a suitable target is subject to market conditions, due diligence outcomes, and shareholder approvals.
• Liquidity Constraints: As of December 31, 2025, KVAC had limited cash and current assets relative to current liabilities, resulting in a low current ratio of 0.01, which may limit operational flexibility outside the trust account.
• Dependence on Trust Account Assets: The company’s substantial assets are held in a trust account, which are restricted and intended for use in the business combination. Any claims or reductions in the trust account could affect the per-share redemption value.
• Regulatory and Market Risks: Potential acquisition targets, especially those based in China or other complex jurisdictions, may expose KVAC to regulatory uncertainties and geopolitical risks.
• Integration and Growth Risks: Post-business combination, the company must successfully integrate and grow the acquired business to create shareholder value, which involves operational and market risks.

• Keen Vision Acquisition Corp. (KVAC) is a blank check company incorporated in the British Virgin Islands on June 18, 2021, formed to effect a business combination with one or more businesses.
• The company completed its IPO on July 27, 2023, raising gross proceeds of approximately $149.5 million, with additional private placement proceeds of about $6.8 million, which were deposited into a trust account for the benefit of public shareholders.
• KVAC's management team and sponsors have over 55 years of combined experience in entrepreneurship, corporate operations, private equity investments, de-SPAC transactions, and corporate finance, with a focus on biotech, consumer goods, and agriculture sectors.
• The company intends to identify and complete an initial business combination with a growth-focused, leading company in biotech, consumer goods, or agriculture, evaluated based on ESG imperatives.
• KVAC has entered into a letter of intent with Medera and its subsidiary Novoheart for a potential business combination involving pre-clinical human disease modeling and drug discovery technologies.
• The letter of intent replaces a prior merger agreement and sets Novoheart's enterprise valuation at $100 million, with a replacement merger agreement targeted by April 10, 2026.
• The company’s financial snapshot as of December 31, 2025, shows cash and cash equivalents of $11,206 and current assets of $36,756, with current liabilities of approximately $4.06 million, resulting in a current ratio of 0.01 and a cash ratio of 0.
• Net income for the year ended December 31, 2025, was $1.91 million, primarily from dividend income earned on investments held in the trust account, offset by operating costs.
• KVAC’s trust account held approximately $57 million as of December 31, 2025, invested primarily in U.S. Treasury securities and money market funds.
• The company’s business strategy leverages its management’s global networks and operational experience to source acquisition targets with strong growth potential and resilient business models.
• KVAC’s management team has transactional experience including sourcing investments, restructuring, due diligence, executing transactions, implementing business plans, and de-SPAC processes.
• The company’s acquisition criteria include industry leadership, high growth potential, global market nexus, capacity for revenue and earnings growth, resilient business models, and experienced management teams.
• KVAC’s sponsors have agreed to indemnify the trust account to maintain minimum per-share values in case of claims reducing trust assets.
• The company has not yet completed its initial business combination and is subject to the risks typical of SPACs, including the ability to identify and consummate a suitable target business combination.
• Recent news highlights a partnership involving Medera’s Novoheart and Curi Bio for human-based cardiac drug screening, relevant to KVAC’s potential business combination target [N1].